The FDA Type 2a feedback is a modest positive for the ABP-450 program, but with only ~$7M cash runway into Q3 2026, AEON will likely need additional financing before the Type 2b meeting. The massive share dilution (shares more than doubled) and pre-revenue status limit upside. Watch for the Type 2b meeting in H2 2026 as the next major catalyst.
Price Chart
Executive Summary
AEON Biopharma reported Q1 2026 results with a net loss of $11.8M ($-0.29/share), compared to net income of $9.1M ($2.28/share) in Q1 2025, driven by increased operating expenses and fair-value changes on convertible notes. The company highlighted positive FDA Type 2a feedback for its ABP-450 biosimilar program and a strengthened balance sheet from a $6M PIPE and Daewoong note exchange that reduced debt by over 90%. Cash of $6.2M (plus $0.9M from ATM in April) funds operations into Q3 2026, but the pre-revenue clinical-stage biotech faces a binary regulatory catalyst with no near-term revenue.
Key Financial Metrics
Key Facts
- Net loss of $11.8M in Q1 2026 vs net income of $9.1M in Q1 2025, driven by operating expense growth and non-cash fair-value adjustments
- Cash and cash equivalents of $6.2M as of March 31, 2026, plus $0.9M from April ATM, funding operations into Q3 2026
- Convertible notes reduced from $34.6M to $1.5M following Daewoong note exchange, cutting outstanding debt by >90%
- FDA BPD Type 2a meeting provided positive feedback on ABP-450 analytical similarity strategy under 351(k) biosimilar pathway
- Shares outstanding more than doubled to 25.3M from 12.1M at year-end 2025, reflecting PIPE and note exchange issuances
- BPD Type 2b meeting with FDA planned for second half 2026 to discuss remaining development program requirements
Financial Impact
Q1 2026 net loss of $11.8M vs net income of $9.1M in Q1 2025; operating expenses increased to $5.9M from $0.5M; cash burn rate ~$2M/month with runway into Q3 2026
Risk Factors
- Cash runway only into Q3 2026 — likely needs additional financing before next FDA milestone
- Pre-revenue with no approved products; ABP-450 faces long regulatory path with no guarantee of approval
- Massive share dilution (shares outstanding more than doubled from year-end 2025) depresses per-share value
- Single-product pipeline risk — failure of ABP-450 program would be value-destructive
- NYSE American continued listing standards risk flagged in forward-looking statements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001837607-26-000041 |
| Document: aeon-20260514x8k.htm | 0001837607-26-000041 |
| Document: 0001837607-26-000041-index-headers.html | 0001837607-26-000041 |
| Document: 0001837607-26-000041-index.html | 0001837607-26-000041 |
| Document: 0001837607-26-000041.txt | 0001837607-26-000041 |
| 8-K Data (Synthetic) | 0001837607-26-000041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEF 14A | — | awaiting T+5 | — | — |
Oct 23, 2026 3d ago | 8-K | $0.2399 | awaiting T+5 | — | $0.2400 (+0.04%) |
Sep 30, 2026 26d ago | 8-K | $0.3000 $0.3110 | ▲ +3.67% | ▲ +1.75% | $0.2400 (−20.00%) |
Aug 21, 2026 9w ago | 3 | $0.1974 $0.2959 | ▲ +49.90% | ▲ +49.43% | $0.2400 (+21.58%) |
Aug 19, 2026 9w ago | Press Release | $0.1980 $0.2515 | ▲ +27.02% | ▲ +27.41% | $0.2400 (+21.21%) |
Aug 12, 2026 10w ago | Press Release | $0.2706 $0.1931 | ▼ −28.64% | ▼ −26.68% | $0.2400 (−11.31%) |
Jul 23, 2026 13w ago | 8-K | $0.2507 $0.2552 | ▼ −1.79% | ▼ −1.42% | $0.2400 (+4.27%) |
Jul 15, 2026 14w ago | 8-K | $0.2974 $0.2600 | ▲ +12.58% | ▲ +10.91% | $0.2400 (+19.30%) |
Jul 15, 2026 14w ago | 424B4 | $0.2997 $0.2752 | ▲ +8.17% | ▲ +7.19% | $0.2400 (+19.92%) |
Jul 14, 2026 14w ago | EFFECT | $0.3570 $0.2890 | ▲ +19.05% | ▲ +17.75% | $0.2400 (+32.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers